New Drug Application News and Research

RSS
Reversal of ADAR1 hyper-editing with small molecule inhibitor

Reversal of ADAR1 hyper-editing with small molecule inhibitor

UC Davis launches new center to accelerate the development of promising cancer therapies

UC Davis launches new center to accelerate the development of promising cancer therapies

Noramco Announces Submission of Drug Master File for Lisdexamfetamine Dimesylate ─ Active Pharmaceutical Ingredient

Noramco Announces Submission of Drug Master File for Lisdexamfetamine Dimesylate ─ Active Pharmaceutical Ingredient

Combination treatment improves outcomes in advanced kidney cancer patients

Combination treatment improves outcomes in advanced kidney cancer patients

Developments in Engineered T Cells for Type 1 Diabetes

Developments in Engineered T Cells for Type 1 Diabetes

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.